Crescent Capital BDC, Inc. (CCAP)
| Market Cap | 319.09M -38.5% |
| Revenue (ttm) | 156.40M -14.6% |
| Net Income | -3.17M |
| EPS | -0.09 |
| Shares Out | 36.85M |
| PE Ratio | n/a |
| Forward PE | 6.14 |
| Dividend | $1.45 (16.74%) |
| Ex-Dividend Date | Nov 30, 2026 |
| Volume | 104,799 |
| Open | 8.68 |
| Previous Close | 8.76 |
| Day's Range | 8.56 - 8.80 |
| 52-Week Range | 8.40 - 15.18 |
| Beta | 0.62 |
| Analysts | Hold |
| Price Target | 11.96 (+38.11%) |
| Est. Earnings | Nov 11, 2026 |
About CCAP
Crescent Capital BDC, Inc. is as a business development company is a private debt fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.
Financial Performance
In 2025, Crescent Capital BDC's revenue was $167.29 million, a decrease of -15.24% compared to the previous year's $197.36 million. Earnings were $34.51 million, a decrease of -53.14%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CCAP stock is "Hold." The 12-month stock price target is $11.96, which is an increase of 38.11% from the latest price.
News
Crescent Capital BDC price target lowered to $10 from $12 at Raymond James
Raymond James lowered the firm’s price target on Crescent Capital BDC (CCAP) to $10 from $12 and keeps an Outperform rating on the shares. Industry multiple compression and lingering credit…
Crescent Capital BDC price target lowered to $11 from $15.50 at Clear Street
Clear Street analyst Mickey Schleien lowered the firm’s price target on Crescent Capital BDC (CCAP) to $11 from $15.50 and keeps a Buy rating on the shares. The firm says…
Crescent Capital BDC downgraded to Neutral at BofA amid credit stress
As previously reported, BofA analyst Derek Hewett downgraded Crescent Capital BDC (CCAP) to Neutral from Buy with a price target of $10.25, down from $13. The firm views the current…
Crescent Capital BDC downgraded to Neutral from Buy at BofA
BofA analyst Derek Hewett downgraded Crescent Capital BDC (CCAP) to Neutral from Buy with a price target of $10.25, down from $13.
Crescent Capital Group Closes Second CLO Equity Fund at $232 Million
LOS ANGELES--(BUSINESS WIRE)--Crescent Capital Group LP (“Crescent”), one of the leading alternative credit investment firms, announced today the final close of its second captive collateralized loan ...
Crescent Capital BDC price target lowered to $11 from $12 at Wells Fargo
Wells Fargo analyst Finian O’Shea lowered the firm’s price target on Crescent Capital BDC (CCAP) to $11 from $12 and keeps an Equal Weight rating on the shares. The firm…
Crescent Capital BDC price target lowered to $14 from $15 at Ladenburg
Ladenburg analyst Christopher Nolan lowered the firm’s price target on Crescent Capital BDC (CCAP) to $14 from $15 and keeps a Buy rating on the shares. The firm is lowering…
Crescent Capital BDC price target lowered to $12.50 from $13.50 at B. Riley
B. Riley analyst Sean-Paul Adams lowered the firm’s price target on Crescent Capital BDC (CCAP) to $12.50 from $13.50 and keeps a Neutral rating on the shares. The firm updated…
Crescent Capital BDC downgraded to Market Perform at Keefe Bruyette
Keefe Bruyette downgraded Crescent Capital BDC (CCAP) to Market Perform from Outperform with a price target of $12, down from $13. The company’s Q2 results were negative due to a…
Crescent Capital BDC Earnings Call Transcript: Q2 2026
Net investment income declined to $0.36 per share, but earnings exceeded the base dividend. NAV fell to $17.82 per share, mainly due to unrealized losses on non-accruals, while leverage rose above target but is expected to normalize in the second half. Portfolio rotation and de-leveraging remain key priorities.
Crescent Capital BDC Quarterly report: Q2 2026
Crescent Capital BDC has published its Q2 2026 quarterly earnings report on August 11, 2026.
Crescent Capital BDC Earnings release: Q2 2026
Crescent Capital BDC released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Crescent Capital BDC Slides: Q2 2026
Crescent Capital BDC has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
Crescent Capital BDC reports Q2 EPS 36c, consensus 37c
Reports Q2 NAV per share $17.82. The company said, “As of June 30, 2026 and December 31, 2025, the Company had investments in 192 and 184 portfolio companies with an…
Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its Second Quarter Ended June 30, 2026 Financial Results
LOS ANGELES, July 24, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC”) (NASDAQ: CCAP) today announced it will release its financial results for the second quarter ended June 30, 20...
Crescent Capital BDC price target lowered to $13 from $15 at Keefe Bruyette
Keefe Bruyette lowered the firm’s price target on Crescent Capital BDC (CCAP) to $13 from $15 and keeps an Outperform rating on the shares.
Crescent Capital Group Closes Largest Fund in Firm's History with Fourth U.S. Direct Lending Fund, Raising $10.8 Billion in Investable Capital
LOS ANGELES & NEW YORK & BOSTON & CHICAGO--(BUSINESS WIRE)--Crescent Capital Group LP (“Crescent”), one of the leading alternative credit investment firms, announced today the successful final close o...
Crescent Capital BDC price target lowered to $13 from $15 at BofA
BofA analyst Derek Hewett lowered the firm’s price target on Crescent Capital BDC (CCAP) to $13 from $15 and keeps a Buy rating on the shares. The firm is adjusting…
Crescent Capital BDC Transcript: AGM 2026
The meeting confirmed quorum and proceeded with the election of two directors for terms expiring in 2029 and ratified Ernst & Young LLP as auditor for 2026. No shareholder questions were submitted during the session.
Crescent Capital BDC reduced fees a positive, says B. Riley
B. Riley keeps a Neutral rating on Crescent Capital BDC (CCAP) with a $13.50 price target following the “mixed” Q1 report. The biggest positive of the quarter is Crescent management…
Crescent Capital BDC price target lowered to $15 from $16 at Ladenburg
Ladenburg analyst Christopher Nolan lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15 from $16 and keeps a Buy rating on the shares.
Crescent Capital BDC price target lowered to $12 from $13 at Wells Fargo
Wells Fargo analyst Finian O’Shea lowered the firm’s price target on Crescent Capital BDC (CCAP) to $12 from $13 and keeps an Equal Weight rating on the shares. The new…
Crescent Capital BDC downgraded to Perform from Outperform at Oppenheimer
Oppenheimer last night downgraded Crescent Capital BDC (CCAP) to Perform from Outperform with a price target of $16, down from $19. The firm increased Crescent’s equity discount rate by 50…
Crescent Capital BDC downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Crescent Capital BDC (CCAP) to Perform from Outperform with a price target of $16, down from $19.
Crescent Capital BDC Earnings Call Transcript: Q1 2026
NAV and NII declined due to increased non-accruals, especially in healthcare, but portfolio risk ratings remain stable. Management and incentive fees were reduced, the base dividend was reset, and Sun Life completed its acquisition of Crescent Capital.